Rhizen Pharmaceuticals S.A. to present preclinical data of RP6530 (dual PI3K delta/gamma inhibitor) in Multiple Myeloma

La Chaux-de-Fonds, Switzerland, Nov. 18, 2014 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces a poster presentation for RP6530, a novel dual PI3K delta/gamma inhibitor in Multiple Myeloma.

--- Data to be presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, November 18-21, 2014, Barcelona, Spain

--- RP6530 synergizes with standard Multiple Myeloma (MM) therapy such as bortezomib (VELCADE ® ) in MM representative cell lines

--- Efficacy study in a MM1S systemic mouse xenograft model indicates that RP6530 increases survival with the effect being superior to standard doses of bortezomib

About RP6530:

RP6530 is a highly selective and orally active dual PI3K delta/gamma inhibitor with efficient translation of activity through enzyme, cell, and whole blood-based studies. Besides inhibiting growth of immortalized cancerous cell lines and primary patient leukemic/lymphoma cells, RP6530 plays a significant role in modulation of tumor microenvironment at clinically achievable concentrations. A Phase 1 dose-escalation trial evaluating the safety and efficacy of RP6530 in patients with relapsed/refractory hematological malignancies is currently ongoing (ClinicalTrials.gov Identifier: NCT02017613).

Details of the poster and oral presentations:

-- Poster Title: Dual PI3K delta/gamma inhibition by RP6530 accentuates bortezomib activity in multiple myeloma cell lines

· Poster Session: Molecular Targeted Agents I

· Presentation Date: 20 November 2014

· Abstract Number: 332

· Poster Board Number: P112

About Rhizen Pharmaceuticals S.A.:

Rhizen Pharmaceuticals is an innovative, clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer, immune and metabolic disorders. Since its establishment in 2008, Rhizen has created a diverse pipeline of proprietary drug candidates targeting several cancers and immune associated cellular pathways. Rhizen is headquartered in La-Chaux-de-Fonds, Switzerland. For additional information, please visit Rhizen's website, www.rhizen.com.

CONTACT: Kumar V. Penmetsa, Ph.D. Vice President, Corporate Development Rhizen Pharmaceuticals S.A. Telephone: +1-267-207-5707 Email: kvp@rhizen.com

Source:Rhizen Pharmaceuticals SA